Kiyoto Shiga1, Ken-Ichi Nibu2, Yasushi Fujimoto3, Takahiro Asakage4, Akihiro Homma5, Hiroki Mitani6, Takenori Ogawa7, Kenji Okami8, Shigeyuki Murono9, Shigeru Hirano10, Tsutomu Ueda11, Nobuhiro Hanai12, Kiyoaki Tsukahara13, Ichiro Ota14, Seiichi Yoshimoto15, Takeshi Shinozaki16, Shigemichi Iwae17, Katsunori Katagiri1, Daisuke Saito1, Naomi Kiyota18, Makoto Tahara19, Fumiaki Takahashi20, Ryuichi Hayashi16. 1. Department of Head and Neck Surgery, Iwate Medical University School of Medicine, Yahaba, Japan. 2. Department of Otolaryngology-Head and Neck Surgery, Kobe University Graduate School of Medicine, Kobe, Japan. 3. Department of Otorhinolaryngology, Nagoya University Graduate School of Medicine, Nagoya, Japan. 4. Department of Head and Neck Surgery, Tokyo Medical and Dental University, Bunkyo-ku, Japan. 5. Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. 6. Department of Head and Neck Surgery, Cancer Institute Hospital of JFCR, Tokyo, Japan. 7. Department of Otolaryngology-Head and Neck Surgery, Tohoku University Hospital, Sendai, Japan. 8. Department of Otolaryngology, Tokai University School of Medicine, Hiratsuka, Japan. 9. Department of Otolaryngology, Fukushima Medical University, Fukushima, Japan. 10. Department of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan. 11. Department of Otorhinolaryngology-Head and Neck Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Higashihiroshima, Japan. 12. Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan. 13. Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Shinjuku-ku, Japan. 14. Department of Otolaryngology-Head and Neck Surgery, Nara Medical University, Kashihara, Japan. 15. Department of Head and Neck Surgery, National Cancer Center Hospital, Tokyo, Japan. 16. Department of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa, Japan. 17. Department of Head and Neck Surgery, Hyogo Cancer Center, Akashi, Japan. 18. Department of Medical Oncology/Hematology, Kobe University Hospital Cancer Center, Kobe, Japan. 19. Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan. 20. Division of Medical Engineering, Department of Information Science, Iwate Medical University, Yahaba, Japan.
Abstract
OBJECTIVES: This study aimed to evaluate the efficacy of chemoradiotherapy (CRT) for patients with advanced cancer of the external auditory canal (EAC) by analyzing the outcome of the patients. METHODS: This is a multi-institutional retrospective survey, and we reviewed the medical records of the subjects. A total of 181 patients with tumor (T)3 or T4 tumor in 17 institutions were enrolled. Further analysis was performed for 74 patients who underwent CRT under curative intent. RESULTS: Overall 5-year survival rates of the patients who underwent CRT (n = 74) were 54.6%. Those of the patients who underwent CRT with modified TPF (docetaxel, cisplatin [CDDP], and 5-fluorouracil) regimen (n = 50) and CRT with CDDP regimens (n = 24) were 64.4% and 36.7%, respectively. Significant differences were observed between these two groups. CONCLUSION: Given the tendency that head and neck surgeons prefer CRT for advanced larger cancer of the EAC, CRT for advanced EAC cancer using the modified TPF regimen showed good clinical outcomes. LEVEL OF EVIDENCE: 4 Laryngoscope, 131:E870-E874, 2021.
OBJECTIVES: This study aimed to evaluate the efficacy of chemoradiotherapy (CRT) for patients with advanced cancer of the external auditory canal (EAC) by analyzing the outcome of the patients. METHODS: This is a multi-institutional retrospective survey, and we reviewed the medical records of the subjects. A total of 181 patients with tumor (T)3 or T4 tumor in 17 institutions were enrolled. Further analysis was performed for 74 patients who underwent CRT under curative intent. RESULTS: Overall 5-year survival rates of the patients who underwent CRT (n = 74) were 54.6%. Those of the patients who underwent CRT with modified TPF (docetaxel, cisplatin [CDDP], and 5-fluorouracil) regimen (n = 50) and CRT with CDDP regimens (n = 24) were 64.4% and 36.7%, respectively. Significant differences were observed between these two groups. CONCLUSION: Given the tendency that head and neck surgeons prefer CRT for advanced larger cancer of the EAC, CRT for advanced EAC cancer using the modified TPF regimen showed good clinical outcomes. LEVEL OF EVIDENCE: 4 Laryngoscope, 131:E870-E874, 2021.
Authors: Cindy H Nabuurs; Wietske Kievit; C René Leemans; Conrad F G M Smit; Michiel W M van den Brekel; Robert J Pauw; Bernard F A M van der Laan; Jeroen C Jansen; Martin Lacko; Weibel W Braunius; Chunfu Dai; Xunbei Shi; Giovanni Danesi; Jan Bouček; Robert P Takes; Henricus P M Kunst Journal: Head Neck Date: 2022-05-13 Impact factor: 3.821